Hypofunction of the N-methyl-d-aspartate (NMDA) subtype of glutamate receptors may be
involved in the pathophysiology of schizophrenia. Many studies have investigated …

It is long acknowledged that the N-methyl d-aspartate receptor co-agonist, d-serine, plays a
crucial role in several N-methyl d-aspartate receptor-mediated physiological and …

The potential implication of a decrease in the function of N-methyl-d-aspartate receptors
(NMDARs) in the pathophysiology of schizophrenia has long been hypothesised …

BACKGROUND: We previously reported a reduction in serum levels of d-serine, an
endogenous co-agonist of the N-methyl-D-aspartate (NMDA) receptor, in schizophrenia …

OBJECTIVES: Based on the hypothesis of NMDA receptor hypofunction in schizophrenia,
plasma glycine, l-serine, and d-serine levels have been studied, since they could serve as …

BACKGROUND: D-serine, a selective full agonist at the glycine site of N-methyl-d-aspartate
glutamate receptor, might presently be the compound of choice for counteracting the …

OBJECTIVE: d-Serine is a full agonist at the glycine site on the N-methyl-d-aspartate
(NMDA) receptor. Previous administration of d-serine to schizophrenic patients taking …

We have measured the concentrations of free d-serine post-mortem in the prefrontal cortex,
parietal cortex, cerebellum and spinal cord from individuals with and without (controls) …

Abstract d‐Serine is a co‐agonist at the NMDA receptor glycine‐binding site. Early studies
have emphasized a glial localization for d‐serine. However the nature of the glial cells has …

Alzheimer's disease (AD) is a severe neurodegenerative disorder still in search of effective
methods of diagnosis. Altered levels of the NMDA receptor co-agonist, d-serine, have been …